Platform technology

ODT Pharma's two initial products have substantial safety, efficacy and manufacturing data in place to reach the market quickly.

ODT has exclusive rights to develop products in this platform for use across non-human species.

The orally disintegrating platform offers significant value for novel products, generics, line extensions, and life cycle management.

Successful proof of concept studies have been done in:

• Canine
• Feline
• Bovine
• Equine

Numerous types of actives have been delivered transmucosally using this platform:

• Gastric pH agent
• Parasiticide
• NSAID
• Sedative
• Bronchodilator
• Antibiotic